Review
Published · Updated · 1 min read
PDCO: paediatric investigation plans for benznidazole and golimumab
What it means for practice
The abstract does not support changes to paediatric prescribing: it describes recommendations on investigation plans, not clinical outcomes. The relevant decisions should be checked before drawing practice implications.
Summary
“PDCO – News” summarises recommendations from a Paediatric Committee (PDCO) meeting held, according to the abstract, in July 2026. Its main focus is paediatric investigation plans (PIPs) for several medicines and their alignment with regulatory requirements.
What was reported
- Votes on PIPs for benznidazole in Chagas disease and golimumab in Crohn’s disease are mentioned.
- Waivers are reported for finasteride/tadalafil and celecoxib/ciprofloxacin.
- Compliance is reported as confirmed for studies of Lactobacillus reuteri and onasemnogene abeparvovec.
Limits of the available information
The abstract emphasises the importance of these recommendations for assessing the safety and efficacy of treatments in children. However, it provides no clinical outcomes, participant numbers, age groups, doses or safety measures. The outcomes of individual votes, the scope of the waivers and the criteria for confirmed compliance are not specified.
The information therefore primarily concerns paediatric drug development. The abstract alone is insufficient to draw conclusions about the benefits and risks of a particular treatment or changes to its use in children.
Source
-
PDCO – News.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
